NurExone Biologic Company Description

NurExone Biologic Inc., operates as a pharmaceutical technology company.

It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications.

The company was founded in 2020 and is based in Toronto, Canada.

NurExone Biologic Inc.

Country	Canada
Founded	2020
Industry	Biotechnology
Sector	Healthcare
CEO	Lior Shaltiel

Contact Details

Address: 1 First Canadian Place Toronto, Alberta M5X 1G5 Canada
Website	nurexone.com

Stock Details

Ticker Symbol	NRX
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Dr. Lior Shaltiel Ph.D.	Chief Executive Officer and Director
Yoram Drucker	Co-Founder, Vice President of Strategic Development and Chairman
Eran Ovadya M.B.A.	Chief Financial Officer, Financial Director and Secretary
Gabriel Eldor	Co-Founder and Business Development Manager
Dr. Shulamit Levenberg Ph.D.	Co-Founder and Member of Scientific Advisory Board
Dr. Daniel Offen Ph.D.	Co-Founder and Member of Scientific Advisory Board
Prof. Nahshon Knoller M.D.	Head of the neurosurgery department at Shiba and Member of Scientific Advisory Board
Dr. Ina Sarel Ph.D.	Head of CMC, Quality and Regulation
Nirit Drori-Carmi M.Sc.	Head of Bioprocess Development
Dr. Limor Chen Ph.D.	Head of Scientific Collaboration and External Partnerships